Novavax shares are climbing due to recent regulatory approvals for its updated protein-based COVID-19 vaccine in major jurisdictions, validating its licensing partnership strategy. This, combined with strong Q2 financial performance and broader biotech sector strength, is driving investor confidence.
Novavax received regulatory approvals from the U.S. FDA, EU, and Japan for its updated COVID-19 vaccine, Nuvaxovid, ahead of the 2026-2027 autumn vaccination campaign. This validates their pivoted operating model, which relies on licensing partnerships with companies like Sanofi and Takeda to distribute vaccines, reducing internal commercial overhead and generating high-margin royalties. This news, coupled with a strong Q2 financial performance and positive sentiment in the broader biotech sector (driven by Merck and Moderna's cancer vaccine trial success), is driving NVAX stock higher. For traders, this presents a short-term opportunity in NVAX due to renewed confidence in its product and business model, with long-term implications tied to the sustained success of its partnership strategy and future vaccine development.